Originally designated for the treatment of Type 2 diabetes, the drugs have become blockbuster medications as they have been increasingly linked to weight loss and other metabolic health benefits
In this work, we explore how the brain-gut axis, immune activation, microbial dysbiosis, intestinal barrier dysfunction, bile acid malabsorption and serotonin signalling interplay to drive IBS
However, subsequent approval of certain GLP-1RAs for adolescents in December 2022 coincided with changing treatment patterns
This calibrated potency pattern differentiates retatrutide from GLP-1 monotherapies and GLP-1/GIP dual agonists, contributing to its broad metabolic effects
doi: 10.3389/fmicb.2022.979719
It falls under the glucagon-like peptide-1 (GLP-1) inhibitor medication class, which helps control blood sugar levels and may lead to weight loss as a side effect